Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years Old

NCT04865497 PHASE2 COMPLETED

The purpose of this study is to evaluate immunogenicity and safety of S.flexneriza-S.sonnei Bivalent Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old.

Details

Lead sponsor	Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Phase	PHASE2
Status	COMPLETED
Enrolment	1050
Start date	Sat Jan 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Dec 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Dysentery
• Dysentery, Bacillary

Interventions

• S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
• S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
• S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
• Haemophilus b Conjugate Vaccine

Countries

China